Skip to content

Study · Observational study · 2023

2 results

Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.

Resnik SR, Targett D, Resnik BI

Journal of drugs in dermatology : JDD1 Sept 2023Cited by 2 (Europe PMC)

PMID37683058 (opens in a new tab)DOI10.36849/jdd.7126 (opens in a new tab)PepBankPUB-37683058
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with erythropoietic protoporphyria, the share who said EPP affected their lives very much or a lot fell from 75% before treatment to 11% after the first afamelanotide implant and to 0% after each later implant.

    In plain wordsIn people with EPP, the share who said the disease affected their lives a lot fell from 75% to 0% after afamelanotide implants.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseEPP affecting patients' lives very much or a lot
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Photosensitivity and sun tolerance · Skin and wound
    Studied dose
    Dose not stated · implantAs given in this study (human).

    Measurements

    EPP affected life very much or a lot
    75%
    before treatment
    EPP affected life very much or a lot
    11%
    after 1st implant
    EPP affected life very much or a lot
    0%
    after each subsequent implant

    Source sentences

    Summary
    Prior to treatment, 75% of patients indicated that EPP affected their lives "very much" or "a lot". This number fell to 11% after the 1st implant and to 0% after each subsequent implant.
    1 context sentence
    Summary · context
    In this study, patients receiving afamelanotide filled out questionnaires assessing the benefit of treatment.
  2. 02HumanObservational studyEfficacy outcome

    In patients with erythropoietic protoporphyria, the number who willingly ventured outside increased with each subsequent afamelanotide implant.

    In plain wordsIn people with EPP, more patients willingly went outside with each later afamelanotide implant.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasePatients willingly venturing outside
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Photosensitivity and sun tolerance · Skin and wound
    Studied dose
    Dose not stated · implantAs given in this study (human).

    Source sentences

    Summary
    The number of patients that willingly ventured outside increased with each subsequent implant.
    1 context sentence
    Summary · context
    In this study, patients receiving afamelanotide filled out questionnaires assessing the benefit of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.